ZYMtronix is a biotechnology startup headquartered in Ithaca, NY. We improve biocatalysis for pharmaceutical production.

**Problem:** Pharma is pushing manufacturing innovation to lead cost-competition and production management.

**Our Solution:**

- **IronZYM**
  - **Advantages:**
    - Uses Existing Materials, Off-the-Shelf
    - No Chemicals Or Energy Needed
    - 30X Faster Than Traditional Methods
    - Immobilized & Recyclable (Multiple-Use)
    - Safe and Biodegradable

- **SHIELD**

**Results:** Reduced Costs, Green Chemicals, High Quality

**Our Value:****

- A universal biocatalyst immobilization toolkit
- A profitable, flexible, platform
- Leading solution in large, underserved, evolving markets
- Focused on future profit growth

**Our Team:**

- Dr. Stéphane Corgié, PhD (CEO-CTO) -Inventor
- Juan Diego Alonso, JD-MBA (CBO-CFO)

**Our Milestones:**

- 2013: Start-up
- 2015: Lab Scale Operation
- 2016: Pilot Plant

**Intellectual Property:** ZYMtronix is the licensee from Cornell University of all exclusive rights to PCT/US12/28392, PCT/US13/63441. IP (designs & applications) and (know-how) synthesis, are being developed in-house; We retain the patent services of Scully, Scott, Murphy & Presser, LLP and Kaplan LLP.

**Our Asks:**

- Strategic Partnership
- $60,000 for a 2:1 NSF Phase 1B match
- $300,000 used to cover past and future licensing costs, scaling-up and employee salaries

**ZYMtronix Catalytic Systems:** Kevin M. McGovern Family Center for Venture Development in the Life Sciences 414A-1 Weill Hall, Cornell University, Ithaca, NY 14853, USA

**ZYMtronix in Motion©**